Thera-Tech

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies for unmet medical needs in HIV and oncology. The company's commercial portfolio includes Egrifta SV (tesamorelin), the only FDA-approved treatment for excess abdominal fat in HIV-infected patients with lipodystrophy, and Trogarzo (ibalizumab), a first-in-class monoclonal antibody for multidrug-resistant HIV-1. Theratechnologies is also advancing a proprietary SORT1+ Technology platform, which utilizes peptide-drug conjugates (PDCs) to deliver cytotoxic agents directly to sortilin-expressing cancer cells. In September 2025, the company was acquired by Future Pak for approximately $254 million, transitioning from a public entity to a private subsidiary. The company continues to explore expanded indications for its metabolic health portfolio, including the use of tesamorelin for the treatment of MASH.